In clinical research, as in so many other areas of life these days, one must have the wisdom to know the difference between a challenging scenario that calls for a digital solution versus a more practical approach.
Are uses of messaging tactics termed “nudges”—intended to influence a decision without the participant’s awareness—ethically questionable during the informed consent process for clinical trials?
If only employees would return to the office, “then what?” is the question one expert hopes senior life sciences leaders and human resources departments will carefully consider.
It is crucial to improve diversity, equity, and inclusion (DEI) in clinical trials for the health and well-being of everyone.
While oncology has been slower to adopt decentralized clinical trials than other medical specialties, many oncologists realize this type of service could be a game-changer for cancer research and treatments.